What are the possible causes of a total bilirubin of 8 mg/dL with modest alkaline phosphatase (≈107 U/L) and AST/ALT (~58 U/L) in a morbidly obese patient without alcohol use, presenting with jaundice, epigastric tenderness, and CT evidence of cholelithiasis with a small pericholecystic fluid collection, who is currently receiving cefazolin (Ancef) for methicillin‑susceptible Staphylococcus aureus (MSSA) bacteremia?

Acute Cholecystitis with Sepsis-Associated Cholestasis

The most likely diagnosis in this patient is acute cholecystitis complicated by sepsis-associated cholestasis from concurrent MSSA bacteremia, creating a mixed cholestatic-hepatocellular pattern with disproportionately elevated bilirubin.

Primary Diagnostic Considerations

The laboratory pattern—total bilirubin 8 mg/dL with only modest alkaline phosphatase (107 U/L) and AST/ALT (58 U/L)—represents a disproportionate hyperbilirubinemia that is characteristic of sepsis-associated cholestasis 1. This pattern, where bilirubin elevation exceeds what would be expected from the degree of alkaline phosphatase and aminotransferase elevation, should be considered an early warning sign of underlying infection, even without fever or leukocytosis 1.

Key Differential Diagnoses:

1. Acute Cholecystitis (Primary Process)

• CT findings of cholelithiasis with pericholecystic fluid and epigastric tenderness strongly suggest acute cholecystitis
• Choledocholithiasis can cause dramatic liver test elevations: AST/ALT >1000 U/L occurs in 6.1% of cases and total bilirubin >10 mg/dL in 4.7% 2
• However, this patient's aminotransferases are only mildly elevated (~58 U/L), making isolated choledocholithiasis less likely as the sole explanation

2. Sepsis-Associated Cholestasis (Complicating Factor)

• The patient has documented MSSA bacteremia requiring cefazolin
• Sepsis-associated cholestasis characteristically produces disproportionate bilirubin elevation compared to alkaline phosphatase and aminotransferases 1
• This pattern develops even in the absence of obvious septic symptoms 1
• The combination of biliary tract infection with systemic bacteremia creates a synergistic cholestatic effect

3. Obesity-Related Hepatic Dysfunction

• Morbid obesity independently affects liver function tests beyond NAFLD through oxidative stress, inflammation, and insulin resistance 3
• However, obesity typically causes mild aminotransferase elevations with normal or slightly decreased bilirubin 3
• This does not explain the marked hyperbilirubinemia

4. Drug-Induced Liver Injury from Cefazolin

• While cefazolin can affect liver tests, controlled studies show no clinically significant changes in bilirubin, alkaline phosphatase, AST, or ALT 4
• The FDA label does not list hepatotoxicity as a significant adverse effect 4
• This is an unlikely primary cause

Recommended Diagnostic Approach

Following the algorithmic approach from established guidelines 5, 6, 7:

Immediate Steps:

1. Fractionate the bilirubin to determine conjugated vs. unconjugated fractions 6, 7

   • If predominantly conjugated (>50% of total): confirms hepatocellular disease or cholestasis
   • If predominantly unconjugated: consider hemolysis (given bacteremia) or Gilbert's syndrome (unlikely with this degree of elevation)

2. Obtain right upper quadrant ultrasound to assess:

   • Common bile duct diameter (normal <6-7 mm)
   • Presence of choledocholithiasis
   • Gallbladder wall thickening and pericholecystic fluid
   • Biliary ductal dilatation

3. Check additional markers:

   • Gamma-glutamyltransferase (GGT) to confirm hepatic origin of alkaline phosphatase 6
   • Prothrombin time/INR and albumin to assess synthetic function 6
   • Lipase to evaluate for concurrent pancreatitis
   • Lactate and inflammatory markers (CRP, procalcitonin) to gauge sepsis severity

If ultrasound shows biliary obstruction or dilated common bile duct (>6 mm):

• Proceed to MRCP or ERCP for therapeutic intervention 2, 7
• Choledocholithiasis with obstruction requires urgent decompression

If ultrasound is unrevealing:

• Consider CT with IV contrast or MRCP to evaluate for:
  • Acalculous cholecystitis
  • Hepatic abscess
  • Other metastatic infectious foci from bacteremia 8

Clinical Pitfalls and Caveats

Critical Warning: Do not attribute all abnormalities to a single diagnosis. This patient has two concurrent processes:

1. Biliary tract disease (cholecystitis/possible choledocholithiasis)
2. Systemic MSSA bacteremia with sepsis-associated cholestasis

Common Mistakes to Avoid:

• Don't assume obesity alone explains the findings – while NAFLD is common in obesity, it doesn't cause bilirubin 8 mg/dL with jaundice 3

• Don't delay surgical consultation – acute cholecystitis with pericholecystic fluid in a septic patient may require urgent cholecystectomy or percutaneous drainage

• Don't overlook metastatic infection – S. aureus bacteremia causes metastatic infection in >33% of cases, including hepatic/splenic abscesses 8. Consider additional imaging if fever persists or bacteremia doesn't clear within 48 hours

• Don't perform extensive hepatitis workup immediately – the clinical context (gallstones, bacteremia, appropriate lab pattern) makes viral hepatitis, autoimmune hepatitis, or Wilson's disease extremely unlikely 5, 7

Expected Clinical Course

If this represents acute cholecystitis with sepsis-associated cholestasis:

• Bilirubin and aminotransferases should decrease by 50-80% within 1-8 days after source control and appropriate antibiotics 2
• Persistent elevation beyond this timeframe warrants expanded workup for alternative diagnoses
• The sepsis-associated cholestatic component should resolve as bacteremia clears

Regarding cefazolin therapy: Cefazolin is appropriate for MSSA bacteremia and is actually the preferred agent over antistaphylococcal penicillins, with demonstrated noninferiority for mortality (15.0% vs 17.0%) and lower rates of acute kidney injury (13.9% vs 19.6%) 9, 8. Continue current antibiotic therapy.

Source Control Priority

The most critical intervention is achieving source control 8:

• Surgical evaluation for cholecystectomy (may need to be delayed if patient too unstable)
• Percutaneous cholecystostomy tube if surgery contraindicated
• ERCP if choledocholithiasis confirmed
• Removal of any infected intravascular catheters

Without source control, antibiotics alone will not resolve the cholestatic picture or prevent mortality from complicated cholecystitis.